Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Casa D, Sung S, Mosquera JM, Rao R. Fine-needle aspiration biopsy of growing teratoma syndrome as a diagnostic pitfall of metastatic adenocarcinoma. Diagn Cytopathol. 2022;50(2):E71-E75.

Velu P, Cong L, Rand S, Qiu Y, Zhang Z, Zhang J, et al. Rapid detection of SARS-CoV-2 variants of concern by single nucleotide polymorphism genotyping using TaqMan assays. Diagn Microbiol Infect Dis. 2022;104(4):115789.

Gulve N, Su C, Deng Z, Soldan SS, Vladimirova O, Wickramasinghe J, et al. DAXX-ATRX regulation of p53 chromatin binding and DNA damage response. Nat Commun. 2022;13(1):5033.

Boyraz B, Watkins JC, Soubeyran I, Bonhomme B, Croce S, Oliva E, et al. Cystic Granulosa Cell Tumors of the Ovary: An Analysis of 80 Cases of an Often Diagnostically Challenging Entity. Arch Pathol Lab Med. 2022;146(12):1450-1459.

Rosen DB, Murphy EA, Gejman RS, Capili A, Friedlander RL, Rand S, et al. Cytokine response over the course of COVID-19 infection in pregnant women. Cytokine. 2022;154:155894.

Adhikari S, Guha D, Mohan C, Mukherjee S, Tyler JK, Das C. Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. Subcell Biochem. 2022;100:3-65.

Suryawanshi H, Yang H, Lubetzky M, Morozov P, Lagman M, Thareja G, et al. Detection of infiltrating fibroblasts by single-cell transcriptomics in human kidney allografts. PLoS One. 2022;17(6):e0267704.

Chen J, San SS, Kung A, Tomasek M, Liu D, Rodgers W, et al. Direct-from-specimen microbial growth inhibition spectrums under antibiotic exposure and comparison to conventional antimicrobial susceptibility testing. PLoS One. 2022;17(2):e0263868.

Orea-Soufi A, Paik J, Bragança J, Donlon TA, Willcox BJ, Link W. FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci. 2022;43(12):1070-1084.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, et al. The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Mol Oncol. 2022;16(12):2384-2395.